// App-Quantinova.ai

: MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody

Researchers

Presenter

  • Shaji K Kumar

Principal Investigators

  • Alfred L. Garfall

  • Suzanne Trudel

  • Enrique M. Ocio

  • Emma Scott

  • Lin HUANG

  • Xuewen Ma

  • Yunsi Olyslager

  • Payal Thakkar

  • Lixia Pei

  • Christoph Heuck

  • Evangelos Terpos

Medical Centers

  • Marques de Valdecilla University Hospital, Santander, Spain

  • Janssen Research & Development, Beerse, Belgium

  • University of Athens, Athens, Greece

  • Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

  • Mayo Clinic, Rochester, MN

  • PRINCESS MARGARET CANCER CENTRE, Toronto, ON, Canada

  • Janssen Research & Development, Spring House, PA

  • Janssen Research & Development, Raritan, NJ

Locations

  • Spain

  • Greece

  • United States

  • Belgium

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Multiple Myeloma

  • Cytokine release syndrome

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved